In equine ophthalmology, natamycin is compounded as an aqueous ophthalmic suspension for fungal keratitis caused by Aspergillus spp., Fusarium spp., and Candida spp.; the molecule binds ergosterol in susceptible fungal membranes and shows negligible corneal epithelial penetration, so clinical activity is concentration-dependent at the tear film and corneal surface. A representative suspension contains micronized veterinary-grade natamycin at 1% w/v, 3% w/v, or 5% w/v, with polysorbate 80 as a wetting agent at 0.02% w/v to 0.1% w/v and hydroxypropyl methylcellulose as a viscosity modifier at 0.5% w/v to 1.0% w/v; sodium chloride is added to adjust osmolality to 280 mOsm/kg to 320 mOsm/kg, and benzalkonium chloride at 0.01% w/v may be used as a preservative in multi-dose containers. Processing is aseptic rather than terminal-autoclaved because natamycin is heat-sensitive; the micronized API is dispersed under high shear in a jacketed vessel at 15°C to 25°C, air is removed by vacuum degassing to prevent suspension caking, and the finished suspension is filled into amber low-density polyethylene bottles to limit light-induced degradation. The particle-size distribution is controlled to a D90 of ≤10 μm as a compounding target to minimize corneal irritation and to align with particulate-matter expectations under USP <789>, while sterility is verified under USP <71> and preservative efficacy under USP <51>; potency release is determined by high-performance liquid chromatography against a natamycin reference standard. The resulting 5% w/v suspension is the most frequently encountered extemporaneous concentration for equine keratitis, whereas 1% w/v is used when smaller corneal lesions or feline patients require lower particulate load. In all cases the suspension is stored at 2°C to 8°C after reconstitution and protected from light; freeze-thaw cycles are not permitted because they cause irreversible particle aggregation. Batch-to-batch variance in suspending-agent lot properties must be monitored because a viscosity drop below 15 mPa·s shortens corneal residence time, while viscosity above 80 mPa·s produces epiphora and poor retention.

What Limits Absorption-Based Efficacy in Natamycin Tablets and Capsules for Crop Candidiasis?

Avian crop candidiasis caused by Candida albicans in turkeys, broilers, and psittacine birds is treated with oral natamycin because the molecule remains in the gastrointestinal lumen; systemic absorption is negligible, and efficacy depends on direct contact with the mucosal surface over sufficient residence time. Tablet formulations for this indication contain natamycin at 50 mg, 100 mg, or 200 mg per unit, microcrystalline cellulose at 30% w/w to 60% w/w as a dry binder, crospovidone at 2% w/w to 5% w/w as a superdisintegrant, and magnesium stearate at 0.5% w/w to 1.0% w/w; capsule blends replace the compression excipients with lactose monohydrate and colloidal silicon dioxide at 0.2% w/w. Roller compaction is preferred over wet granulation because natamycin degrades under elevated heat and moisture; the granulation process is conducted in a dehumidified suite at ≤40% RH and 20°C to 25°C, with roller compaction followed by milling to a granule D50 of 200 μm to 500 μm. Tablet compression is set to achieve hardness of 6 kp to 10 kp and friability ≤1% under USP <1216>; disintegration is tested under USP <701> in water at 37°C, and uniformity of dosage units under USP <905> is applied with acceptance value ≤15. Because dissolution of a poorly water-soluble molecule does not predict systemic absorption, potency and disintegration are used as release controls rather than in vitro dissolution correlation; water content is limited to ≤5% w/w by USP <921>. The finished tablets are coated with a light-protective hydroxypropyl methylcellulose film and packaged in amber high-density polyethylene bottles with desiccant. Operational boundaries include avoiding direct compression at ambient relative humidity above 60% and excluding sodium starch glycolate from blends that will be stored under high-moisture conditions, because the resulting wicking can destabilize the natamycin crystal surface and reduce potency. Published pharmacokinetic data for this exact tablet configuration in psittacine birds is limited; the above process controls are established from formulation stability studies rather than target-animal tissue depletion trials.

Dusting Powder and Granule Dispersions for Dermatophyte Lesions

Topical natamycin powders are used against Microsporum canis, Trichophyton mentagrophytes, Trichophyton verrucosum, and Malassezia pachydermatis in cattle, horses, dogs, and cats; the API is formulated at 0.1% w/w to 2% w/w in a dusting-powder base of kaolin 70% w/w to 85% w/w, zinc oxide 5% w/w to 10% w/w, and purified talc, with the base selected to maintain a dry, non-occlusive environment over exudative ringworm lesions. Granules intended for extemporaneous suspension contain natamycin at 1% w/w, lactose monohydrate as filler, povidone K30 at 2% w/w as a binder, and anhydrous colloidal silicon dioxide at 0.5% w/w; the granulation liquid is water, but wet mass is tray-dried at 40°C to a loss on drying of ≤2% w/w because natamycin is heat-labile. Geometric dilution is performed in a low-shear tumble blender at 15 rpm for 20 min, and the final powder is passed through a 100 μm screen to break agglomerates; a D90 of the API below 25 μm is maintained for even lesion coverage. Non-sterile release testing follows USP <61> and USP <62>, with absence of Staphylococcus aureus and Pseudomonas aeruginosa in 1 g; potency is determined by HPLC, and water activity is maintained below 0.60 to prevent fungal germination during storage. The finished dusting powder is applied twice daily to clipped, cleaned lesions, while the granules are reconstituted with purified water to a 1 mg/mL to 10 mg/mL suspension immediately before use. Copper, iron, and other heavy-metal contact surfaces are excluded from the manufacturing train because of natamycin incompatibility with polyvalent cations; high-shear blending is also avoided because local heat generation can reduce potency and alter particle-size distribution.

Because natamycin is practically insoluble in water and heat-labile, the injectable route in veterinary medicine is confined to sterile aqueous suspensions intended for local cavity irrigation, not intravenous administration. Published data for systemic injectable natamycin in target animal species is limited; therefore, the following compounding controls are derived from sterile suspension design rather than clinical pharmacokinetic trials. A local irrigation suspension contains natamycin at 5 mg/mL to 25 mg/mL, sodium carboxymethylcellulose at 0.3% w/v, polysorbate 80 at 0.1% w/v, and sodium chloride to adjust osmolality to 280 mOsm/kg to 300 mOsm/kg; the pH is adjusted with sodium hydroxide or hydrochloric acid to 6.0 to 7.0. The process is aseptic throughout: the vehicle is steam-sterilized, allowed to cool, and then sterile micronized natamycin is dispersed under high shear in a closed isolator; membrane filtration is not used because it would remove the suspended drug, and autoclaving is rejected because it causes potency loss. The suspension is degassed before filling into Type I borosilicate glass vials sealed with bromobutyl rubber stoppers; sterility is confirmed under USP <71>, bacterial endotoxins under USP <85>, and particulate matter under USP <788>. Equine guttural pouch irrigation and bovine uterine lavage are the most commonly discussed local applications in the veterinary literature, but published treatment outcome data for this specific configuration is limited. The operational boundary is strict: the suspension is not suitable for intravenous administration, and systemic polyene toxicity is not expected when the treated cavity is intact and mucosal surfaces are not extensively ulcerated. Sterile compounding falls under USP <797>, and extralabel use in food-producing species requires veterinary oversight under 21 CFR Part 530.

Feed-Grade Premix Carriers and Moisture-Challenged Feed Preservation

In feed preservation, natamycin is applied as a micro-level antifungal agent to suppress yeast and mold proliferation in high-moisture feed raw materials, complete mixed rations, and liquid by-products; it is not used as a zootechnical growth promoter and is not absorbed from the gastrointestinal tract of animals consuming treated feed. A feed premix contains natamycin at 1% w/w, 2% w/w, or 5% w/w on a calcium carbonate or wheat middlings carrier, with silicon dioxide at 0.5% w/w to 1.0% w/w as an anticaking agent and moisture held to ≤10% w/w by USP <921>. The manufacturing process suspends the API in purified water, sprays the suspension onto the carrier in a ribbon mixer, and dries at 45°C under vacuum to avoid thermal degradation; blend uniformity is verified by HPLC and expressed as relative standard deviation ≤5%. Retention of the premix in bulk storage requires a dry, light-protected silo at ≤25°C; alkaline feed matrices with pH above 8 accelerate natamycin degradation and are excluded. The relevant feed-additive registration pathway in the European Union is Regulation (EC) No 1831/2003, and yeast and mold enumeration in finished feed uses ISO 21527-1; however, the numeric inclusion rate in final feed is jurisdiction-dependent and published data for this specific configuration is limited. Oxidizing agents and sulfites must not be co-mixed in the same premix, and silo bridging occurs when moisture exceeds 10% w/w because the carrier becomes cohesive.

When Otitis Externa Solutions Require Antifungal Contact with Malassezia pachydermatis

Canine and feline otitis externa complicated by Malassezia pachydermatis is treated with natamycin otic instillation when first-line azoles are unavailable or resistance is suspected; the formulation is a semi-aqueous suspension because natamycin is not freely soluble in water. The otic suspension contains natamycin at 0.1% w/v to 1% w/v, propylene glycol at 40% w/w to 70% w/w as the dominant solvent and humectant, glycerin at 10% w/w to 20% w/w, and purified water as the remainder; the pH is adjusted to 5.0 to 6.5, a range in which natamycin is stable and the outer ear tolerates the dose. The API is dispersed under high shear at 20°C to 25°C, and the finished product is filled into amber dropper bottles; light exposure is controlled because natamycin undergoes photodegradation. The suspension is not terminally sterilized, but microbial limits are controlled under USP <61> and USP <62>, and preservative effectiveness is assessed under USP <51> when a multi-dose container is used. Viscosity is adjusted with a microcrystalline cellulose/carboxymethylcellulose sodium blend at 0.5% w/w to 1.5% w/w to prolong contact with the external ear canal. The operational boundary is that the product is indicated for otitis externa only; a ruptured tympanic membrane requires withdrawal of the formulation because propylene glycol and suspended particulate can enter the middle ear and cause irritation. Storage above 25°C accelerates potency loss, and freezing is prohibited because suspension flocculation becomes irreversible. Published clinical data for natamycin otic preparations in dogs is limited; the above parameters are based on otic suspension design and stability studies.